Skip to main content

Advertisement

SpringerLink
Log in

Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Purpose. Serum postoperative matrix metalloproteinase 2 (MMP-2) level is a predictor of outcome in node positive breast cancer and can be used to stratify patients into low and high risk groups. Our aim was to determine how clodronate treatment influences MMP-2 associated clinical outcome.

Patients and methods. Women with primary node-positive breast cancer were randomized to control group or to receive oral clodronate for 3 years. Adjuvant chemo- or endocrine therapy was given to all patients. The follow-up time for all patients was 5 years. MMP-2 and MMP-9 levels were quantitatively measured from the serum of 252 patients before and after 1 year clodronate treatment using enzyme-linked immunoassays.

Results. In clodronate-treated patients, postoperative MMP-2 levels did not predict 5-year disease-free survival or overall survival (DFS, in low MMP-2 group (<5.32 ng/ml, median) 53% versus in high MMP-2 group (>median) 63%, p=NS; OS, 68% versus 63%, p=NS). When the patients were grouped according to serum MMP-2 levels, survival rates among patients with low MMP-levels were better in control than clodronate treated patients (DFS, 82% versus 53%, p = 0.003; OS, 91% versus 68%, p=0.014). Among patients with high serum MMP-2 levels, no significant difference in DFS or OS was found between control and clodronate groups. In multivariate analysis of low risk patients, independent predictors for DFS were treatment, age, nodal and PgR status, and those for OS treatment together with nodal and ER status. During 12 months follow-up, MMP-2 levels increased significantly more in clodonate receiving patients than in controls (p = 0.002). In comparison, when the patients were grouped according to MMP-9 levels, clodronate also impaired DFS among patients with low MMP-9 levels (82% versus 53%, p = 0.02), but no influence on OS was observed (83% versus 70%, p = 0.09).

Conclusions. Clodronate interferes with the prognostic value of serum MMP-2. Clodronate has a negative impact on outcome among patients with low serum MMP-2 and MMP-9 levels, while no such influence is observed among patients with high MMP-2 and MMP-9 levels.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. InstitutionalAuthorNameGroup EBCTC (1998) ArticleTitlePolychemotherapy for early breast cancer: an overview of the randomised trials Lancet 352 930–942

    Google Scholar 

  2. InstitutionalAuthorNameGroup EBCTC (1998) ArticleTitleTamoxifen for early breast cancer: an overview of the randomised trials Lancet 351 1451–1467

    Google Scholar 

  3. JR Green (2002) ArticleTitleBisphosphonates in cancer therapy Curr Opin Oncol 14 609–615 Occurrence Handle12409650 Occurrence Handle1:CAS:528:DC%2BD38XosFegtLw%3D

    PubMed  CAS  Google Scholar 

  4. GR Mundy (2002) ArticleTitleMetastasis to bone: causes, consequences and therapeutic opportunities Nat Rev Cancer 2 584–593 Occurrence Handle12154351 Occurrence Handle1:CAS:528:DC%2BD38XlslGqsLo%3D

    PubMed  CAS  Google Scholar 

  5. S Boissier S Magnetto L Frappart B Cuzin FH Ebetino PD Delmas P Clezardin (1997) ArticleTitleBisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices Cancer Res 57 3890–3894 Occurrence Handle9307266 Occurrence Handle1:CAS:528:DyaK2sXmtFehsrk%3D

    PubMed  CAS  Google Scholar 

  6. P Heikkila O Teronen M Moilanen YT Konttinen R Hanemaaijer M Laitinen P Maisi G Pluijm Particlevan der JD Bartlett T Salo T Sorsa (2002) ArticleTitleBisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines Anticancer Drugs 13 245–254 Occurrence Handle11984068 Occurrence Handle1:CAS:528:DC%2BD38XjsFajsro%3D

    PubMed  CAS  Google Scholar 

  7. O Teronen P Heikkila YT Konttinen M Laitinen T Salo R Hanemaaijer A Teronen P Maisi T Sorsa (1999) ArticleTitleMMP inhibition and downregulation by bisphosphonates Ann N Y Acad Sci 878 453–465 Occurrence Handle1:CAS:528:DyaK1MXkslemsL0%3D Occurrence Handle10415748

    CAS  PubMed  Google Scholar 

  8. G Pluijm Particlevan der H Vloedgraven E Beek Particlevan L Wee-Pals Particlevan der C Lowik S Papapoulos (1996) ArticleTitleBisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro J Clin Invest 98 698–705 Occurrence Handle10.1172/JCI118841 Occurrence Handle8698861

    Article  PubMed  Google Scholar 

  9. O Fromigue L Lagneaux JJ Body (2000) ArticleTitleBisphosphonates induce breast cancer cell death in vitro J Bone Miner Res 15 2211–2221 Occurrence Handle11092402 Occurrence Handle1:CAS:528:DC%2BD3cXnvVKltL0%3D

    PubMed  CAS  Google Scholar 

  10. MV Lee EM Fong FR Singer RS Guenette (2001) ArticleTitleBisphosphonate treatment inhibits the growth of prostate cancer cells Cancer Res 61 2602–2608 Occurrence Handle11289137 Occurrence Handle1:CAS:528:DC%2BD3MXisVSks7g%3D

    PubMed  CAS  Google Scholar 

  11. SG Senaratne G Pirianov JL Mansi TR Arnett KW Colston (2000) ArticleTitleBisphosphonates induce apoptosis in human breast cancer cell lines Br J Cancer 82 1459–1468 Occurrence Handle10780527 Occurrence Handle1:CAS:528:DC%2BD3cXivFGisbs%3D

    PubMed  CAS  Google Scholar 

  12. S Boissier M Ferreras O Peyruchaud S Magnetto FH Ebetino M Colombel P Delmas JM Delaisse P Clezardin (2000) ArticleTitleBisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases Cancer Res 60 2949–2954 Occurrence Handle10850442 Occurrence Handle1:CAS:528:DC%2BD3cXjvFOltrY%3D

    PubMed  CAS  Google Scholar 

  13. P Fournier S Boissier S Filleur J Guglielmi F Cabon M Colombel P Clezardin (2002) ArticleTitleBisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats Cancer Res 62 6538–6544 Occurrence Handle12438248 Occurrence Handle1:CAS:528:DC%2BD38XovFOksrk%3D

    PubMed  CAS  Google Scholar 

  14. SS Virtanen HK Vaananen PL Harkonen PT Lakkakorpi (2002) ArticleTitleAlendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway Cancer Res 62 2708–2714 Occurrence Handle1:CAS:528:DC%2BD38XjtlGrtLw%3D Occurrence Handle11980672

    CAS  PubMed  Google Scholar 

  15. IJ Diel EF Solomayer SD Costa C Gollan R Goerner D Wallwiener M Kaufmann G Bastert (1998) ArticleTitleReduction in new metastases in breast cancer with adjuvant clodronate treatment N Engl J Med 339 357–363 Occurrence Handle9691101 Occurrence Handle1:CAS:528:DyaK1cXltl2msLw%3D

    PubMed  CAS  Google Scholar 

  16. T Powles S Paterson JA Kanis E McCloskey S Ashley A Tidy K Rosenqvist I Smith L Ottestad S Legault M Pajunen A Nevantaus E Mannisto A Suovuori S Atula J Nevalainen L Pylkkanen (2002) ArticleTitleRandomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer J Clin Oncol 20 3219–3224 Occurrence Handle12149294 Occurrence Handle1:CAS:528:DC%2BD38XmsF2rsrs%3D

    PubMed  CAS  Google Scholar 

  17. T Saarto C Blomqvist P Virkkunen I Elomaa (2001) ArticleTitleAdjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial J Clin Oncol 19 10–17 Occurrence Handle11134190 Occurrence Handle1:CAS:528:DC%2BD3MXot1Whuw%3D%3D

    PubMed  CAS  Google Scholar 

  18. J Westermarck VM Kahari (1999) ArticleTitleRegulation of matrix metalloproteinase expression in tumor invasion The FASEB journal: official publication of the Federation of American Societies for Experimental Biology 13 781–792 Occurrence Handle1:CAS:528:DyaK1MXjtFGksrs%3D

    CAS  Google Scholar 

  19. MD Sternlicht Z Werb (2001) ArticleTitleHow matrix metalloproteinases regulate cell behavior Annual Review of Cell and Developmental Biology 17 463–516 Occurrence Handle11687497 Occurrence Handle1:CAS:528:DC%2BD3MXos1Omsbs%3D

    PubMed  CAS  Google Scholar 

  20. MJ Bissell D Radisky (2001) ArticleTitlePutting tumours in context Nat Rev Cancer 1 46–54 Occurrence Handle10.1038/35094059 Occurrence Handle1:STN:280:DC%2BD387mvVOhtw%3D%3D Occurrence Handle11900251

    Article  CAS  PubMed  Google Scholar 

  21. R Hirvonen A Talvensaari-Mattila P Paakko T Turpeenniemi-Hujanen (2003) ArticleTitleMatrix metalloproteinase-2 (MMP-2) in T(1-2)N0 breast carcinoma Breast cancer research and treatment 77 85–91 Occurrence Handle12602907 Occurrence Handle1:CAS:528:DC%2BD38XovVCltLk%3D

    PubMed  CAS  Google Scholar 

  22. A Talvensaari-Mattila P Paakko G Blanco-Sequeiros T Turpeenniemi-Hujanen (2001) ArticleTitleMatrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen adjuvant therapy Breast cancer research and treatment 65 55–61 Occurrence Handle11245340 Occurrence Handle1:CAS:528:DC%2BD3MXhvFektbg%3D

    PubMed  CAS  Google Scholar 

  23. A Talvensaari-Mattila P Paakko T Turpeenniemi-Hujanen (1999) ArticleTitleMMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma. Breast cancer research and treatment 58 287–293 Occurrence Handle10718490 Occurrence Handle1:STN:280:DC%2BD3c7otFCiug%3D%3D

    PubMed  CAS  Google Scholar 

  24. S Leppä T Saarto L Vehmanen C Blomqvist I Elomaa (2004) ArticleTitleA high serum MMP-2 level is associated with an adverse prognosis in node-positive breast carcinoma Clin Cancer Res 10 1057–1063 Occurrence Handle14871985

    PubMed  Google Scholar 

  25. E Laack A Kohler C Kugler T Dierlamm C Knuffmann G Vohwinkel A Niestroy N Dahlmann A Peters J Berger W Fiedler DK Hossfeld (2002) ArticleTitlePretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer Ann Oncol 13 1550–1557 Occurrence Handle12377642 Occurrence Handle1:STN:280:DC%2BD38nitVWrtA%3D%3D

    PubMed  CAS  Google Scholar 

  26. Y Shou T Hirano Y Gong Y Kato K Yoshida T Ohira N Ikeda C Konaka Y Ebihara F Zhao H Kato (2001) ArticleTitleInfluence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer Br J Cancer 85 1706–1712 Occurrence Handle11742492 Occurrence Handle1:CAS:528:DC%2BD38XnsVChtw%3D%3D

    PubMed  CAS  Google Scholar 

  27. T Saarto C Blomqvist M Valimaki P Makela S Sarna I Elomaa (1997) ArticleTitleClodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. Br J Cancer 75 602–605 Occurrence Handle9052418 Occurrence Handle1:CAS:528:DyaK2sXhslWitrg%3D

    PubMed  CAS  Google Scholar 

  28. T Saarto C Blomqvist M Valimaki P Makela S Sarna I Elomaa (1997) ArticleTitleChemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients J Clin Oncol 15 1341–1347 Occurrence Handle9193325 Occurrence Handle1:CAS:528:DyaK2sXivVehsr8%3D

    PubMed  CAS  Google Scholar 

  29. TJ Powles E McCloskey AH Paterson S Ashley VA Tidy A Nevantaus K Rosenqvist J Kanis (1998) ArticleTitleOral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer J Natl Cancer Inst 90 704–708 Occurrence Handle9586668 Occurrence Handle1:CAS:528:DyaK1cXjtlSiu7k%3D

    PubMed  CAS  Google Scholar 

  30. T Saarto C Blomqvist J Risteli L Risteli S Sarna I Elomaa (1998) ArticleTitleAminoterminal propeptide of type I procollagen (PINP) correlates to bone loss and predicts the efficacy of antiresorptive therapy in pre- and post-menopausal non-metastatic breast cancer patients Br J Cancer 78 240–245 Occurrence Handle9683300 Occurrence Handle1:CAS:528:DyaK1cXltFWlsrY%3D Occurrence Handle10.1038/bjc.1998.471

    Article  PubMed  CAS  Google Scholar 

  31. T Hiraga PJ Williams GR Mundy T Yoneda (2001) ArticleTitleThe bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases Cancer Res 61 4418–4424 Occurrence Handle11389070 Occurrence Handle1:CAS:528:DC%2BD3MXktlWjsr0%3D

    PubMed  CAS  Google Scholar 

  32. A Sasaki BF Boyce B Story KR Wright M Chapman R Boyce GR Mundy T Yoneda (1995) ArticleTitleBisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice Cancer Res 55 3551–3557 Occurrence Handle7627963 Occurrence Handle1:CAS:528:DyaK2MXnsFGhsrw%3D

    PubMed  CAS  Google Scholar 

  33. T Michigami T Hiraga PJ Williams M Niewolna R Nishimura GR Mundy T Yoneda (2002) ArticleTitleThe effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs Breast Cancer Res Treat 75 249–258 Occurrence Handle12353814 Occurrence Handle1:CAS:528:DC%2BD38XmsFWmtb8%3D

    PubMed  CAS  Google Scholar 

  34. ME Stearns M Wang (1998) ArticleTitleAlendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice Clin Exp Metastasis 16 693–702 Occurrence Handle10211982 Occurrence Handle1:CAS:528:DyaK1MXivFequ7s%3D

    PubMed  CAS  Google Scholar 

  35. S Derenne M Amiot S Barille M Collette N Robillard P Berthaud JL Harousseau R Bataille (1999) ArticleTitleZoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment J Bone Miner Res 14 2048–2056 Occurrence Handle10620064 Occurrence Handle1:CAS:528:DC%2BD3cXkslWqsA%3D%3D

    PubMed  CAS  Google Scholar 

  36. A Talvensaari-Mattila P Paakko M Hoyhtya G Blanco-Sequeiros T Turpeenniemi-Hujanen (1998) ArticleTitleMatrix metalloproteinase-2 immunoreactive protein- A marker of aggressiveness in breast carcinoma Cancer 83 1153–1162 Occurrence Handle9740080 Occurrence Handle1:CAS:528:DyaK1cXmtlegsrg%3D

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Helsinki University Central Hospital, P.O. Box 180, FIN-00029, Helsinki, Finland

    S. Leppä, T. Saarto, L. Vehmanen, C. Blomqvist & I. Elomaa

  2. Department of Oncolgy, University of Uppsala, Sweden

    C. Blomqvist

Authors
  1. S. Leppä
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Saarto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Vehmanen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Blomqvist
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I. Elomaa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Leppä.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leppä, S., Saarto, T., Vehmanen, L. et al. Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer. Breast Cancer Res Treat 90, 117–125 (2005). https://doi.org/10.1007/s10549-004-3722-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-004-3722-5

Keywords

Search

Navigation